abdominal pain case studies
Posted by admin on 4 June, 2010
No comments yet
This item was filled under [ Most Popular ]
Press Release
Merck & Co. Inc. Posted on:03 Jun 10 Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy …
Operation intestinal worms – Ascariasis bolus
